Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.
Martin Maron, MD, discusses the results of the IMPROVE-HCM trial and how it informs the community on the potential of plozasiran.
Results of EMPACT-MI suggest use of empagliflozin was not associated with a statistically significant reduction in a composite of death and heart failure hospitalization.
CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.
1. In this randomized controlled trial, omalizumab was superior to placebo in increasing the reaction threshold to food allergens among participants with multiple food allergies. 2. The most common adverse event associated with omalizumab was injection-site reaction. Evidence Rating Level: 1 (Excellent) Study Rundown: Food allergy affects approximately 10% of the population, many of whom